TABLE 5.
Vitek 2 and CLSI M100S 26th edition breakpoints that differ for P. aeruginosa and A. baumannii
| Antimicrobiala | BPb | MIC (μg/ml) by organism |
|||||
|---|---|---|---|---|---|---|---|
|
P. aeruginosac |
A. baumannii |
||||||
| S | I | R | S | I | R | ||
| Doripenem | V2 | ≤2 | ≤1 | ||||
| CLSI | ≤2 | 4 | ≥8 | ≤2 | 4 | ≥8 | |
| Imipenem | V2 | ≤4 | 8 | ≥16 | ≤4 | 8 | ≥16 |
| CLSI | ≤2 | 4 | ≥8 | ≤2 | 4 | ≥8 | |
| Meropenem | V2 | ≤4 | 8 | ≥16 | ≤4 | 8 | ≥16 |
| CLSI | ≤2 | 4 | ≥8 | ≤2 | 4 | ≥8 | |
| TZP | V2 | ≤64/4 | ≥128/4 | ||||
| CLSI | ≤16/4 | 32/4–64/4 | ≥128/4 | ||||
a
TZP, piperacillin-tazobactam.
b
BP, breakpoint used to interpret MIC results; V2, Vitek 2 reported breakpoints; CLSI, M100S 26th edition breakpoints.
c
R, resistant; I, intermediate; S, susceptible.